2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention

[1] Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: best in-clinic practices. Prev Med Rep. 2022; 27:101819. ThongtangN SukmawanR LlanesEJB LeeZV Dyslipidemia management for primary prevention of cardiovascular events: best in-clinic practices Prev Med Rep. 2022 27 101819 Search in Google Scholar

[2] Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:111–88. MachF BaigentC CatapanoAL KoskinasKC CasulaM BadimonL 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J. 2020 41 111 88 Search in Google Scholar

[3] Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38:2459–72. FerenceBA GinsbergHN GrahamI RayKK PackardCJ BruckertE Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur Heart J. 2017 38 2459 72 Search in Google Scholar

[4] Gidding SS, Allen NB. Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem. J Am Heart Assoc. 2019; 8:e012924. doi: 10.1161/JAHA.119.012924 GiddingSS AllenNB Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem J Am Heart Assoc. 2019 8 e012924 10.1161/JAHA.119.012924 Open DOISearch in Google Scholar

[5] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44:3720–826. ByrneRA RosselloX CoughlanJJ BarbatoE BerryC ChieffoA 2023 ESC Guidelines for the management of acute coronary syndromes Eur Heart J. 2023 44 3720 826 Search in Google Scholar

[6] Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17:75. doi: 10.5334/gh.1154 RayKK FerenceBA SéverinT BlomD NichollsSJ ShibaMH World Heart Federation Cholesterol Roadmap 2022 Glob Heart. 2022 17 75 10.5334/gh.1154 Open DOISearch in Google Scholar

[7] Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 139:e1082–143. GrundySM StoneNJ BaileyAL BeamC BirtcherKK BlumenthalRS 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines Circulation. 2019 139 e1082 143 Search in Google Scholar

[8] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42:3227–337. VisserenFLJ MachF SmuldersYM CarballoD KoskinasKC BäckM 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Eur Heart J. 2021 42 3227 337 Search in Google Scholar

[9] Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–81. Cholesterol Treatment Trialists' (CTT) Collaboration BaigentC BlackwellL EmbersonJ HollandLE ReithC Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet. 2010 376 1670 81 Search in Google Scholar

[10] Vathesatogkit P, Woodward M, Tanomsup S, Ratanachaiwong W, Vanavanan S, Yamwong S, et al. Cohort profile: the electricity generating authority of Thailand study. Int J Epidemiol. 2012; 41:359–65. VathesatogkitP WoodwardM TanomsupS RatanachaiwongW VanavananS YamwongS Cohort profile: the electricity generating authority of Thailand study Int J Epidemiol. 2012 41 359 65 Search in Google Scholar

[11] Guidelines Review Committee, Nutrition and Food Safety (NFS), SEARO Regional Office for the South East Asia (RGO), WHO South-East Asia. Guideline: sugars intake for adults and children2015. Available from: https://www.who.int/publications/i/item/9789241549028 Guidelines Review Committee, Nutrition and Food Safety (NFS), SEARO Regional Office for the South East Asia (RGO) WHO South-East Asia Guideline: sugars intake for adults and children2015. Available from: https://www.who.int/publications/i/item/9789241549028 Search in Google Scholar

[12] Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients. 2019; 11:338. doi: 10.3390/nu11020338 ChiavaroliL ViguilioukE NishiSK Blanco MejiaS RahelićD KahleováH DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses Nutrients 2019 11 338 10.3390/nu11020338 Open DOISearch in Google Scholar

[13] Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S76–99. EckelRH JakicicJM ArdJD de JesusJM Houston MillerN HubbardVS 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 129 25 Suppl 2 S76 99 Search in Google Scholar

[14] Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018; 378:e34. doi: 10.1056/NEJMoa1800389 EstruchR RosE Salas-SalvadóJ CovasMI CorellaD ArósF Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts N Engl J Med. 2018 378 e34 10.1056/NEJMoa1800389 Open DOISearch in Google Scholar

[15] Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, et al. Consensus statement by the American Association of clinical endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020; 26:1196–224. HandelsmanY JellingerPS GuerinCK BloomgardenZT BrintonEA BudoffMJ Consensus statement by the American Association of clinical endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary Endocr Pract. 2020 26 1196 224 Search in Google Scholar

[16] Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290:140–205. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Atherosclerosis. 2019 290 140 205 Search in Google Scholar

[17] Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, et al. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr. 2007; 86:1611–20. BerglundL LefevreM GinsbergHN Kris-EthertonPM ElmerPJ StewartPW Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states Am J Clin Nutr. 2007 86 1611 20 Search in Google Scholar

[18] Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998; 18:441–9. GinsbergHN Kris-EthertonP DennisB ElmerPJ ErshowA LefevreM Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1 Arterioscler Thromb Vasc Biol. 1998 18 441 9 Search in Google Scholar

[19] Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003; 77:1146–55. MensinkRP ZockPL KesterAD KatanMB Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials Am J Clin Nutr. 2003 77 1146 55 Search in Google Scholar

[20] Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999; 69:30–42. BrownL RosnerB WillettWW SacksFM Cholesterol-lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr. 1999 69 30 42 Search in Google Scholar

[21] Hollaender PL, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 2015; 102:556–72. HollaenderPL RossAB KristensenM Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies Am J Clin Nutr. 2015 102 556 72 Search in Google Scholar

[22] Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, Jessup W, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014; 232:346–60. GyllingH PlatJ TurleyS GinsbergHN EllegårdL JessupW Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease Atherosclerosis. 2014 232 346 60 Search in Google Scholar

[23] Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011; 85:9–28. Musa-VelosoK PoonTH ElliotJA ChungC A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials Prostaglandins Leukot Essent Fatty Acids. 2011 85 9 28 Search in Google Scholar

[24] Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999; 319:1523–8. RimmEB WilliamsP FosherK CriquiM StampferMJ Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors BMJ. 1999 319 1523 8 Search in Google Scholar

[25] Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol. 1995; 15:1917–27. GardnerCD KraemerHC Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis Arterioscler Thromb Vasc Biol. 1995 15 1917 27 Search in Google Scholar

[26] Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166:285–93. NordmannAJ NordmannA BrielM KellerU YancyWSJr BrehmBJ Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials Arch Intern Med. 2006 166 285 93 Search in Google Scholar

[27] Santos FL, Esteves SS, da Costa Pereira A, Yancy WS Jr, Nunes JP. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev. 2012; 13:1048–66. SantosFL EstevesSS da Costa PereiraA YancyWSJr NunesJP Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors Obes Rev. 2012 13 1048 66 Search in Google Scholar

[28] Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. Nutrition. 2014; 30:503–10. KelishadiR MansourianM Heidari-BeniM Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis Nutrition. 2014 30 503 10 Search in Google Scholar

[29] Rouis M, Dugi KA, Previato L, Patterson AP, Brunzell JD, Brewer HB, et al. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol. 1997; 17:1400–6. RouisM DugiKA PreviatoL PattersonAP BrunzellJD BrewerHB Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome Arterioscler Thromb Vasc Biol. 1997 17 1400 6 Search in Google Scholar

[30] Shirai K, Kobayashi J, Inadera H, Ohkubo Y, Mori S, Saito Y, et al. Type I hyperlipoproteinemia caused by lipoprotein lipase defect in lipid-interface recognition was relieved by administration of medium-chain triglyceride. Metabolism. 1992; 41:1161–4. ShiraiK KobayashiJ InaderaH OhkuboY MoriS SaitoY Type I hyperlipoproteinemia caused by lipoprotein lipase defect in lipid-interface recognition was relieved by administration of medium-chain triglyceride Metabolism. 1992 41 1161 4 Search in Google Scholar

[31] Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014; 44:211–21. MannS BeedieC JimenezA Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations Sports Med. 2014 44 211 21 Search in Google Scholar

[32] Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006; 2006:CD003817. ShawK GennatH O'RourkeP Del MarC Exercise for overweight or obesity Cochrane Database Syst Rev. 2006 2006: CD003817 Search in Google Scholar

[33] Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003; 37:283–90. MaedaK NoguchiY FukuiT The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis Prev Med. 2003 37 283 90 Search in Google Scholar

[34] Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022; 328:754–71. ChouR CantorA DanaT WagnerJ AhmedAY FuR Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force JAMA 2022 328 754 71 Search in Google Scholar

[35] Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195–207. RidkerPM DanielsonE FonsecaFA GenestJ GottoAMJr KasteleinJJ Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med. 2008 359 2195 207 Search in Google Scholar

[36] Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 2013:CD004816. doi: 10.1002/14651858.CD004816.pub5 TaylorF HuffmanMD MacedoAF MooreTH BurkeM Davey SmithG Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev. 2013 2013: CD004816 10.1002/14651858.CD004816.pub5 Open DOISearch in Google Scholar

[37] Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374:2021–31. YusufS BoschJ DagenaisG ZhuJ XavierD LiuL Cholesterol lowering in intermediate-risk persons without cardiovascular disease N Engl J Med. 2016 374 2021 31 Search in Google Scholar

[38] Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017; 177:955–65. HanBH SutinD WilliamsonJD DavisBR PillerLB PervinH Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial JAMA Intern Med. 2017 177 955 65 Search in Google Scholar

[39] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360:1623–30. ShepherdJ BlauwGJ MurphyMB BollenEL BuckleyBM CobbeSM Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet. 2002 360 1623 30 Search in Google Scholar

[40] Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013; 20:641–57. NaciH BrugtsJJ FleurenceR TsoiB ToorH AdesAE Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol. 2013 20 641 57 Search in Google Scholar

[41] Nowak MM, Niemczyk M, Florczyk M, Kurzyna M, Paczek L. Effect of statins on all-cause mortality in adults: a systematic review and meta-analysis of propensity score-matched studies. J Clin Med. 2022; 11:5643. doi: 10.3390/jcm11195643 NowakMM NiemczykM FlorczykM KurzynaM PaczekL Effect of statins on all-cause mortality in adults: a systematic review and meta-analysis of propensity score-matched studies J Clin Med. 2022 11 5643 10.3390/jcm11195643 Open DOISearch in Google Scholar

[42] Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther. 2005; 19:403–14. BruckertE HayemG DejagerS YauC BegaudB Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study Cardiovasc Drugs Ther. 2005 19 403 14 Search in Google Scholar

[43] Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; 389:2473–81. GuptaA ThompsonD WhitehouseA CollierT DahlofB PoulterN Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase Lancet. 2017 389 2473 81 Search in Google Scholar

[44] Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 140:e563–95. ArnettDK BlumenthalRS AlbertMA BurokerAB GoldbergerZD HahnEJ 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines Circulation 2019 140 e563 95 Search in Google Scholar

[45] ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023; 46(Suppl 1):S158–90. ElSayedNA AleppoG ArodaVR BannuruRR BrownFM BruemmerD 10. cardiovascular disease and risk management: standards of care in diabetes-2023 Diabetes Care 2023 46 Suppl 1 S158 90 Search in Google Scholar

[46] Wright AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, Buchan I, Emsley R, et al. Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. Circulation. 2020; 142:1925–36. WrightAK Suarez-OrtegonMF ReadSH KontopantelisE BuchanI EmsleyR Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings Circulation. 2020 142 1925 36 Search in Google Scholar

[47] ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–74. ACCORD Study Group GinsbergHN ElamMB LovatoLC CrouseJR3rd LeiterLA Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med. 2010 362 1563 74 Search in Google Scholar

[48] AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365:2255–67. AIM-HIGH Investigators BodenWE ProbstfieldJL AndersonT ChaitmanBR Desvignes-NickensP Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med. 2011 365 2255 67 Search in Google Scholar

[49] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380:11–22. BhattDL StegPG MillerM BrintonEA JacobsonTA KetchumSB Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia N Engl J Med. 2019 380 11 22 Search in Google Scholar

[50] Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Inter Suppl. 2013; 3:259–305. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Inter Suppl. 2013 3 259 305 Search in Google Scholar

[51] Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181–92. BaigentC LandrayMJ ReithC EmbersonJ WheelerDC TomsonC The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet. 2011 377 2181 92 Search in Google Scholar

[52] Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016; 4:829–39. Cholesterol Treatment Trialists' (CTT) Collaboration HerringtonWG EmbersonJ MihaylovaB BlackwellL ReithC Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials Lancet Diabetes Endocrinol. 2016 4 829 39 Search in Google Scholar

[53] Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41:407–77. KnuutiJ WijnsW SarasteA CapodannoD BarbatoE Funck-BrentanoC 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes Eur Heart J. 2020 41 407 77 Search in Google Scholar

[54] Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355:549–59. AmarencoP BogousslavskyJ CallahanA3rd GoldsteinLB HennericiM RudolphAE High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med. 2006 355 549 59 Search in Google Scholar

[55] Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011; 68:1245–51. CallahanA AmarencoP GoldsteinLB SillesenH MessigM SamsaGP Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Arch Neurol. 2011 68 1245 51 Search in Google Scholar

[56] Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52:e364–467. KleindorferDO TowfighiA ChaturvediS CockroftKM GutierrezJ Lombardi-HillD 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association Stroke 2021 52 e364 467 Search in Google Scholar

[57] Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372:2387–97. CannonCP BlazingMA GiuglianoRP McCaggA WhiteJA TherouxP Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med. 2015 372 2387 97 Search in Google Scholar

[58] Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376:1713–22. SabatineMS GiuglianoRP KeechAC HonarpourN WiviottSD MurphySA Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med. 2017 376 1713 22 Search in Google Scholar

[59] Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:2097–107. SchwartzGG StegPG SzarekM BhattDL BittnerVA DiazR Alirocumab and cardiovascular outcomes after acute coronary syndrome N Engl J Med. 2018 379 2097 107 Search in Google Scholar

[60] Eun MY, Jung JM, Choi KH, Seo WK. Statin effects in atrial fibrillation-related stroke: a systematic review and meta-analysis. Front Neurol. 2020; 11:589684. doi: 10.3389/fneur.2020.589684 EunMY JungJM ChoiKH SeoWK Statin effects in atrial fibrillation-related stroke: a systematic review and meta-analysis Front Neurol. 2020 11 589684 10.3389/fneur.2020.589684 Open DOISearch in Google Scholar

[61] Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Peña JM, et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023; 43:e404–42. GoldsteinLB TothPP Dearborn-TomazosJL GiuglianoRP HirshBJ PeñaJM Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association Arterioscler Thromb Vasc Biol. 2023 43 e404 42 Search in Google Scholar

[62] Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022; 53:e282–361. GreenbergSM ZiaiWC CordonnierC DowlatshahiD FrancisB GoldsteinJN 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association Stroke 2022 53 e282 361 Search in Google Scholar

[63] Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849–61. KeechA SimesRJ BarterP BestJ ScottR TaskinenMR Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet. 2005 366 1849 61 Search in Google Scholar

[64] ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363:233–44. ACCORD Study Group, ACCORD Eye Study Group ChewEY AmbrosiusWT DavisMD DanisRP Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med. 2010 363 233 44 Search in Google Scholar

[65] Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; 370:1687–97. KeechAC MitchellP SummanenPA O'DayJ DavisTM MoffittMS Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet. 2007 370 1687 97 Search in Google Scholar

[66] Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023; 44:129–38. RayKK RaalFJ KallendDG JarosMJ KoenigW LeiterLA Inclisiran and cardiovascular events: a patient-level analysis of phase III trials Eur Heart J. 2023 44 129 38 Search in Google Scholar

[67] Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023; 388:1353–64. NissenSE LincoffAM BrennanD RayKK MasonD KasteleinJJP Bempedoic acid and cardiovascular outcomes in statin-intolerant patients N Engl J Med. 2023 388 1353 64 Search in Google Scholar

[68] Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020; 324:2268–80. NichollsSJ LincoffAM GarciaM BashD BallantyneCM BarterPJ Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial JAMA. 2020 324 2268 80 Search in Google Scholar

[69] The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251:351–64. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease JAMA. 1984 251 351 64 Search in Google Scholar

[70] Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017; 23(Suppl 2):1–87. JellingerPS HandelsmanY RosenblitPD BloomgardenZT FonsecaVA GarberAJ American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease Endocr Pract. 2017 23 Suppl 2 1 87 Search in Google Scholar

[71] Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020; 105:dgaa674. doi: 10.1210/clinem/dgaa674 NewmanCB BlahaMJ BoordJB CariouB ChaitA FeinHG Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab. 2020 105 dgaa674. 10.1210/clinem/dgaa674 Open DOISearch in Google Scholar

[72] Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44:4043–140. MarxN FedericiM SchüttK Müller-WielandD AjjanRA AntunesMJ 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes Eur Heart J. 2023 44 4043 140 Search in Google Scholar

[73] Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin Cardiol. 2018; 41:13–9. BudoffM Brent MuhlesteinJ LeVT MayHT RoyS NelsonJR Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study Clin Cardiol. 2018 41 13 9 Search in Google Scholar